Table 2.

Time course of clinical parameters in a patient with NASH

Date	2012	2013	2014	2015	2016	2017	2018	2019	2019	2020	2020
BMI	22.3	22.4	22.3	22.1	22.1	22.2	22.3	22.4	22.4	22.3	22.3
AST (U/L)	69	48	45	48	61	54	47	28	23	20	21
ALT (U/L)	83	60	52	60	79	55	55	33	26	19	19
Plt (10(9)/L)	198	212	227	223	204	214	227	218	228	233	243
FIB-4	2.78	1.99	1.79	1.99	2.29	2.31	1.93	1.58	1.4	1.4	1.47
Mac2BPGi	1.12	0.93	0.99	1.01	1.14	1.03	1.09	0.83	0.72	0.68	0.58
Type4Collagen					209	191	211	186	179	174	165
(ng/ml)
hsCRP (mg/dl)	0.054	0.039	0.042	0.038	0.048	0.039	0.04	0.04	0.023	0.028	0.009
FBS (mg/dl)	158	148	149	163	178	160	156	128	134	114	124
HbA1c (%)	7.8	6.8	7.2	7.6	7.4	6.9	6.6	6.5	6.5	6.4	6.5
IRI (IU/ml)	6.7	6.6	5.7	6.2	5	6.1	5.9	4.4	4.6	4.5	3.8
HOMA-IR	2.61	2.41	2.1	2.5	2.19	2.41	2.27	1.39	1.52	1.26	1.16
TG (mg/dl)	116	155	133	116	132	150	153	73	75	126	89
Total-C (mg/dl)	175	173	193	175	179	151	157	152	141	171	158
HDL-C (mg/dl)	37	34	43	37	41	36	358	41	41	45	43
LDL-C (mg/dl)	115	108	120	115	110	85	88	96	85	101	98
rosuvastatin (mg/day)	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
glimepirid (mg/day)	2	2	2	2	2	2	2	2	2	2	2
sitagliptin (mg/day)	100
linagliptn (mg/day)	5	5	5	5	5	5
omarigliptin (mg/week)							25	25	25	25	25
pioglitazone (mg/day)	15	30	30	30
metoformin (mg/day)					1000	1000	1000	1000	1000	1000	1000
					↑ Liver Biopsy

FIB-4 = age ([yr] x AST [U/L]) / ((PLT [10(9)/L]) x (ALT [U/L])(1/2))

M2BPGi: Mac-2 binding protein glycosylation isomer